Jun 26, 2026
Jun 26, 2026
Jun 26, 2026
Jun 26, 2026
Jun 26, 2026
Jun 26, 2026
Jun 26, 2026
Jun 26, 2026
Revolution Medicines' new drug, daraxonrasib, boasts a 60% reduction in death risk for pancreatic cancer patients. This shift in treatment raises questions about the future of cancer therapies and the battle against this deadly disease.